Thermal Screening for Early Diabetic Peripheral Neuropathy (DPN)

Sponsor
VisionQuest Biomedical LLC (Industry)
Overall Status
Completed
CT.gov ID
NCT03069729
Collaborator
University of New Mexico (Other)
331
1
29.8
11.1

Study Details

Study Description

Brief Summary

The goal of this research is to develop better tools for diagnosing illness of the feet and legs of people who have diabetes. Investigators will use thermal videos of the foot to aid in the refinement of a system designed to detect signs of diabetic peripheral neuropathy (DPN). The team of investigators will also look at diabetic eye disease and how it might relate to diabetic foot disease.

Condition or Disease Intervention/Treatment Phase
  • Other: no intervention

Detailed Description

This study focuses on further development and testing of a microvascular functional imaging system, a computer-based system for screening thermal video images, designed to detect biomarkers of diabetic peripheral neuropathy (DPN). Additionally, severity levels of diabetic retinopathy (DR) will be compared with those of DPN.

All participants in this study will undergo foot exams, thermal imaging of the foot, and standard retinal imaging. These non-invasive assessments will be performed at an initial study visit. Some of the participants will be offered additional study visits. One of the additional visits involves a standard nerve conduction velocity assessment by a neurologist, the other involves a DPN exam by a podiatrist.

Portions of the study take place at University of New Mexico Health Sciences Center (UNM HSC). The research utilizes services of the Clinical Translational Science Center (CTSC).

The study is approved by University of New Mexico Health Sciences Center's Human Research Review Committee (HRRC), which coordinates and supports the activities of the three federally mandated Human Research Review Committees (HRRCs) responsible for reviewing and approving all human research.

Study Design

Study Type:
Observational
Actual Enrollment :
331 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Thermal Screening for Early Diabetic Peripheral Neuropathy (DPN)
Actual Study Start Date :
Mar 8, 2017
Actual Primary Completion Date :
Aug 1, 2019
Actual Study Completion Date :
Sep 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Control group

non-diabetic; no intervention

Other: no intervention
This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.

Diabetics without DPN

diabetics without DPN; no intervention

Other: no intervention
This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.

Diabetics with DPN

diabetics with DPN; no intervention

Other: no intervention
This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.

Outcome Measures

Primary Outcome Measures

  1. Pattern of thermal recovery [24 months]

    The thermal recovery pattern after cold provocation will be different for each group studied.

Secondary Outcome Measures

  1. Correlation of DPN severity levels and DR severity levels [18 months]

    Correlation between severity levels of DR and DPN will be determined. The severity level of DR will be assessed by qualified retinal image readers. Level of severity will be assigned, based on the International Clinical Diabetic Retinopathy Disease Severity Scale, into 5 levels: No apparent retinopathy Mild nonproliferative diabetic retinopathy Moderate nonproliferative diabetic retinopathy Severe nonproliferative diabetic retinopathy Proliferative diabetic retinopathy The severity of DPN will be graded by utilizing data from assessments from a DPN exam performed by an experienced podiatrist, Nerve Conduction Velocity (NCV) test performed by a neurologist, and assessments performed by technicians. Data utilized will include: NVC results Vibration threshold, reported in seconds Monofilament test of protective sensation

Eligibility Criteria

Criteria

Ages Eligible for Study:
35 Years to 76 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

• Must be non-diabetic or diagnosed as diabetic for at least 5 years

Exclusion Criteria:

history of chemotherapy

  • surgery below the knee within the last 2 years

  • fractures below the know within the last 2 years

  • history of stroke

  • body mass index (BMI) greater than 35

  • history of heart failure

  • peacemaker or implantable cardiovascular defibrillator

  • high blood pressure (over 180/100)

  • end-stage renal (kidney) disease or renal (kidney) transplant

  • peripheral edema greater than 2+ (swelling of the feet or hands)

  • diabetic foot ulcers

  • foot sores

  • Raynaud's phenomenon

  • tobacco use within the last month.

  • treatment with glucocorticoids, including:

  • beclomethasone

  • betamethasone

  • budesonide

  • cortisone

  • dexamethasone

  • hydrocortisone

  • methylprednisolone

  • prednisolone

  • prednisone

  • triamcinolone

Contacts and Locations

Locations

Site City State Country Postal Code
1 VisionQuest Biomedical LLC Albuquerque New Mexico United States 87106

Sponsors and Collaborators

  • VisionQuest Biomedical LLC
  • University of New Mexico

Investigators

  • Principal Investigator: Peter Soliz, PhD, VisionQuest Biomedical LLC

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
VisionQuest Biomedical LLC
ClinicalTrials.gov Identifier:
NCT03069729
Other Study ID Numbers:
  • R43DK104578-01
First Posted:
Mar 3, 2017
Last Update Posted:
Oct 12, 2020
Last Verified:
Oct 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by VisionQuest Biomedical LLC
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 12, 2020